ArticleScientific reports2025
A nomogram combining clinical features, O-RADS US, and radiomics based on ultrasound imaging for diagnosing ovarian cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- STL-DeepBDC: A Robust Few-Shot Learning Framework for Multiclass Ovarian Tumor Classification in Ultrasound Outperforms Conventional Transfer Learning.Cancer medicine · 2026Article
- Radiomics and Artificial Intelligence in Ovarian Endometriosis Imaging: A Systematic Review and Critical Appraisal of Emerging Evidence.Bioengineering (Basel, Switzerland) · 2026Review
- Integration of serological markers with O-RADS ultrasound risk stratification achieves high diagnostic accuracy for early ovarian cancer: development and validation of an interpretable model.American journal of cancer research · 2026Article
- A review of ovarian-adnexal reporting and data system and radiomics in ovarian cancer: focus on ultrasound applications.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
We aimed to develop and validate a nomogram for diagnosing ovarian cancer from ovarian masses based on clinical information, O-RADS US, and radiomics. A total of 981 patients with ovarian masses from two centers were randomly divided into the training cohort (n = 686) and the validation cohort (n = 295). We defined the region of interest (ROI) of the tumor by manually drawing the tumor contour on the ultrasound image of the lesion. The radiomics features were extracted from ultrasound images, and the radiomics score was then calculated. O-RADS US characteristics, radiomics score, and clinical features selected using the LASSO algorithm were used to develop O-RADS US + Radscore + Clinical, Radscore + Clinical, and O-RADS US + Clinical models, respectively. Receiver operating characteristic (ROC), decision curve analysis, and calibration curve were used to evaluate the performance of the nomogram models. Age, CA125, O-RADS US, and radiomics score were related to ovarian malignancy through univariate and multivariate logistic regression analyses. In the training and validation datasets, the areas under the ROC curve (AUC) of O-RADS US + Clinical model were 0.830 and 0.815, respectively, and those for the Radscore + Clinical model were 0.876 and 0.867, respectively. The O-RADS US + Radscore + Clinical nomogram model presented improved AUC values of 0.967 in the training group and 0.951 in the validation group, significantly higher than that of Radscore + Clinical and O-RADS US + Clinical models. The calibration curve and the clinical decision curve analysis demonstrated that the nomogram models had high clinical benefits. The O-RADS US + Radscore + Clinical model had the highest net return. Combination nomogram model that integrates clinical features, O-RADS US, and radiomics based on ultrasound image analysis could predict ovarian malignancy with high diagnostic accuracy, indicating that this model might have a role in preoperative diagnosis for differentiating benign and malignant ovarian tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.